Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) EBIT (2022 - 2025)

Corvus Pharmaceuticals has reported EBIT over the past 4 years, most recently at -$12.2 million for Q4 2025.

  • Quarterly results put EBIT at -$12.2 million for Q4 2025, down 50.73% from a year ago — trailing twelve months through Dec 2025 was -$43.0 million (down 55.99% YoY), and the annual figure for FY2025 was -$43.0 million, down 55.99%.
  • EBIT for Q4 2025 was -$12.2 million at Corvus Pharmaceuticals, down from -$10.6 million in the prior quarter.
  • Over the last five years, EBIT for CRVS hit a ceiling of -$5.6 million in Q3 2023 and a floor of -$12.5 million in Q3 2022.
  • Median EBIT over the past 4 years was -$7.1 million (2022), compared with a mean of -$7.9 million.
  • Biggest five-year swings in EBIT: surged 55.42% in 2023 and later plummeted 72.87% in 2025.
  • Corvus Pharmaceuticals' EBIT stood at -$5.7 million in 2022, then increased by 0.26% to -$5.7 million in 2023, then tumbled by 43.43% to -$8.1 million in 2024, then crashed by 50.73% to -$12.2 million in 2025.
  • The last three reported values for EBIT were -$12.2 million (Q4 2025), -$10.6 million (Q3 2025), and -$10.3 million (Q2 2025) per Business Quant data.